• We are available for your help 24/7
  • Email: info@isindexing.com, submission@isindexing.com

Paper Details


Ammula Uhanjali*, Dhulipalla Surekha, Divi Manasa and Venkata Rao Vutla*

Journal Title:World Journal of Pharmaceutical Research

Multiple Sclerosis (MS) is one of the most common neurological disorders especially in North America and in Europe. It affects 400,000 Americans at any one time.MS causes nerves of CNS to degenerate by inflammation of nerves which causes myelin to disappear. As a result CNS impulses that travel along the nerves decelerate causing interference in vision, speech, memory, and writing. Most common symptoms are blurring vision, dizziness, fatigue , weakness, numbness or tingling in arms or legs.MS is diagnosed by Magnetic resonance imaging (MRI).Scientists and doctors have not discovered a permanent cure but discovering out how to treat and manage MS based on his or her type of MS. Usually steroidal and antidepressant drugs are given orally or through intravenously. A person is diagnosed with MS between 20 and 50 years of age, but MS has been diagnosed in children and elderly people. Cause of MS is still unknown. In last 20 years it was found that MS is progressive immunological mediated disease of brain and spinal cord (CNS).MS management draws on many disciplines, such as pharmacists, neurologists, speech therapists, nurses, physiotherapists, counselors.